It is overexpressed in several cancers, especially in HCC, where it activates EMT, decreases the expression levels of E-cadherin and increases the expression levels of the mesenchymal marker vimentin (Xie, et al., 2018). Here, CDH1 is linked to hepatocellular carcinoma.